Patents Examined by Malgorzata A. Walicka
-
Patent number: 7078205Abstract: The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: June 7, 2002Date of Patent: July 18, 2006Assignee: Millennium Pharmaceuticals, Inc.Inventors: Rajasekhar Bandaru, Maria Alexandra Glucksmann, Rachel E. Meyers, Laura A. Rudolph-Owen
-
Patent number: 7074602Abstract: An L-threonine-producing Escherichia coli strain and a method for producing the same are provided. The Escherchia coli strain contains chromosomal DNA with inactivated metJ gene. Therefore, expression repression of threonine biosynthesis genes by a metJ gene product is prevented, thereby producing a high concentration of threonine. Further, a high concentration of L-threonine can be produced in high yield using the method.Type: GrantFiled: August 12, 2004Date of Patent: July 11, 2006Assignee: CJ CorporationInventors: Jae Yong Cho, Byoung Choon Lee, Dae Cheol Kim, Jin Ho Lee, Young Hoon Park
-
Patent number: 7067300Abstract: The present invention provides an improved method for the biological production of 1,3-propanediol from a fermentable carbon source in a single microorganism. In one aspect of the present invention, an improved process for the conversion of glucose to 1,3-propanediol is achieved by the use of an E. coli transformed with the Klebsiella pneumoniae dha regulon genes dhaR, orfY, dhaT, orfX, orfW, dhaB1, dhaB2, dhaB3, and orfZ, all these genes arranged in the same genetic organization as found in wild type Klebsiella pneumoniae. In another aspect of the present invention, an improved process for the production of 1,3-propanediol from glucose using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, and a dehydratase reactivation factor compared to an identical process using a recombinant E. coli containing genes encoding a G3PDH, a G3P phosphatase, a dehydratase, a dehydratase reactivation factor and a 1,3-propanediol oxidoreductase (dhaT).Type: GrantFiled: October 21, 2002Date of Patent: June 27, 2006Assignee: E. I. du Pont de Nemours and CompanyInventors: Mark Emptage, Sharon L. Haynie, Lisa A. Laffend, Jeff P. Pucci, Gregory Marshall Whited
-
Patent number: 7067271Abstract: Disclosed are various forms of an active, isolated ?-secretase enzyme in purified and recombinant form. This enzyme is implicated in the production of amyloid plaque components which accumulate in the brains of individuals afflicted with Alzheimer's disease. Recombinant cells that produce this enzyme either alone or in combination with some of its natural substrates (?-APPwt and ?-APPsw) are also disclosed, as are antibodies directed to such proteins. These compositions are useful for use in methods of selecting compounds that modulate ?-secretase. Inhibitors of ?-secretase are implicated as therapeutics in the treatment of neurodegenerative diseases, such as Alzheimer's disease.Type: GrantFiled: November 28, 2000Date of Patent: June 27, 2006Assignee: Elan Pharmaceuticals, Inc.Inventors: John P. Anderson, Guriqbal Basi, Minh Tam Doan, Normand Frigon, Varghese John, Michael Power, Sukanto Sinha, Gwen Tatsuno, Jay Tung, Shuwen Wang, Lisa McConlogue
-
Patent number: 7060455Abstract: The present disclosure describes DNA damage endonucleases which exhibit broad specificity with respect to the types of structural aberrations in double stranded DNA. These enzymes recognize double stranded DNA with distortions in structure, wherein the distortions result from photoproducts, alkylation, intercalation, abasic sites, mismatched base pairs, insertion deletion loops, cisplatin adducts and other types of base damage (for example, uracil resulting from cytosine deamination). The UVDE (Uve1p) of Schizosaccharomyces pombe, certain truncated forms of that UVDE (lacking from about 100 to about 250 amino acids of N-terminal sequence) and certain endonucleases from Homo sapiens, Neurospora crassa, Bacillus subtilis, Bacillus anthracis, Methanococcus jannaschii, and Deinococcus radiodurans. The present disclosure further provides methods for cleaving double stranded DNA having structural distortions as set forth herein using the exemplified endonucleases or their stable, functional truncated derivatives.Type: GrantFiled: November 28, 2000Date of Patent: June 13, 2006Assignee: Emory UniversityInventors: Paul W. Doetsch, Angela M. Avery, Balveen Kaur
-
Patent number: 7056513Abstract: The present invention is directed to novel telomerase nucleic acids and amino acids. In particular, the present invention is directed to nucleic acid and amino acid sequences encoding various telomerase protein subunits and motifs, including the 123 kDa and 43 kDa telomerase protein subunits of Euplotes aediculatus, and related sequences from Schizosaccharomyces, Saccharomyces sequences, and human telomerase. The present invention is also directed to polypeptides comprising these telomerase protein subunits, as well as functional polypeptides and ribonucleoproteins that contain these subunits.Type: GrantFiled: April 26, 2001Date of Patent: June 6, 2006Assignees: Geron Corporation, Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 7056693Abstract: The present invention relates to in vitro and ex vivo methods of screening for modulators, homologues, and mimetics of lethal factor mitogen activated protein kinase kinase (MAPKK) protease activity, as well as methods of treating cancer by administering LF to transformed cells.Type: GrantFiled: April 22, 2005Date of Patent: June 6, 2006Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Nicholas Duesbery, Craig Webb, Stephen Leppla, George Vande Woude
-
Patent number: 7045294Abstract: The present invention relates an isolated human Site-1 Protease promoter region. The invention also relates to screening methods for agents decreasing the expression of Site-1 protease and thereby being potentially useful for the treatment of medical conditions related to obesity and/or diabetes.Type: GrantFiled: April 20, 2004Date of Patent: May 16, 2006Assignee: Biovitrum ABInventors: Lars Abrahamsén, Jonas Ekblom, Margareta Forsgren, Jan Hörling, Per Johansson
-
Patent number: 7041787Abstract: The present invention relates to MMP regulators that comprise new synthetic peptides, that comprise amino acid sequences structurally similar to those of MMP binding region of TIMPs, coupled to zinc chelators. The invention also relates to methods for making these MMP regulators and their use for the treatment of chronic and acute wounds and for the treatment of angiogenesis-associated diseases.Type: GrantFiled: December 29, 2000Date of Patent: May 9, 2006Assignee: Kimberly-Clark Worldwide, Inc.Inventors: Stephen Quirk, David John Tyrrell
-
Patent number: 7037671Abstract: The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.Type: GrantFiled: June 12, 2003Date of Patent: May 2, 2006Assignees: Millennium Pharmaceuticals, Inc., Bayer CorporationInventors: William James Cook, Rory A. J. Curtis, Frank Spaltmann
-
Patent number: 7033815Abstract: The present invention makes use of a chimeric gene that, when incorporated into an appropriate host, results in the overproduction of S-adenosylmethionine without the need to supply the host with a source of untransformed methionine. The need for the methionine source is eliminated because the appropriately chosen host manufactures the amino acid on its own, and when the host is modified by the inclusion of a chimeric gene of the present invention, it transforms the methionine that is produced into S-adenosylmethionine. In addition, the same chimeric gene causes accumulation of methionine and increase in folate content in the same host. One form of the present invention is a fused gene encoding for methylene tetrahydrofolate reductase (MTHFR) made up of an N-terminal domain from a yeast organism and a C-terminal domain from a plant species. An example of a suitable plant species is Arabidopsis thaliana. An example of a suitable yeast organism is Saccharomyces cerevisiae.Type: GrantFiled: March 29, 2002Date of Patent: April 25, 2006Assignees: Board of Regents, the University of Texas System, University of FloridaInventors: Dean R. Appling, Andrew D. Hanson, Sanja Roje, Rhonda K. Raymond
-
Patent number: 7033812Abstract: The invention concerns a novel ?-secretase, a method of partially purifying this novel ?-secretase, and its use in assays to screen for potential drug candidates against Alzheimer's disease and other neurological diseases. The novel ?-secretase has an estimated molecular weight of about 32–39 kDa or 22–26 kDa in HEK293 cell membrane extracts and human brain samples, respectively, as calculated from radiation inactivation analysis, and has a pH optimum at about pH 6.5–7.0.Type: GrantFiled: December 18, 2003Date of Patent: April 25, 2006Assignees: Scios Inc., Eli Lilly and CompanyInventors: Ziyang Zhong, Barbara Cordell, Diana Hom Quon, Yu-Wang Liu, Qiang Xu, Frauke Schimmöller, Paul Andrew Hyslop, Edward Marion Johnstone, Sheila Parks Little, Steven Wyatt Queener, Tinggui Yin
-
Patent number: 7005262Abstract: The present invention is directed to methods of identifying in a sample nucleic acids that encode human telomerase reverse transcriptase (hTRT) or its fragments. The present invention is also directed to oligonucleotide primers used in such methods. The invention is further directed to PCR products that hybridize under stringent conditions to a polynucleotide encoding hTRT, as well as hybridization complexes comprising one strand of a cellular hTRT nucleic acid and one strand of nucleic acid comprising a recombinant or synthetic fragment of hTRT.Type: GrantFiled: January 18, 2002Date of Patent: February 28, 2006Assignees: Geron Corporation, The Regents of the University of ColoradoInventors: Thomas R. Cech, Joachim Lingner, Toru Nakamura, Karen B. Chapman, Gregg B. Morin, Calvin B. Harley, William H. Andrews
-
Patent number: 7001993Abstract: Human antithrombin variants showing a high protease inhibitory activity even in the absence of heparin wherein at least one of the amino acids at positions 78, 278, 378 and 380 in the amino acid sequence of natural human antithrombin is substituted by another amino acid. Preferable examples thereof are human antithrombin variants wherein the amino acid at position 78 is substituted by Phe; the amino acid at position 278 is substituted by Ala, Arg, Asn, Gly, His, Tyr or Val; the amino acid at position 378 is substituted by Lys, Asn or Val; and/or the amino acid at position 380 is substituted by Ala, Asp, Gly, His, lie, Leu, Asn, Pro, Arg, Thr, Tyr or Val.Type: GrantFiled: June 22, 2000Date of Patent: February 21, 2006Assignee: Aventis Pharma Ltd.Inventor: Takehiko Koide
-
Patent number: 6998257Abstract: The present invention provides new recombinantly produced vanadium haloperoxidases. The enzymes are useful in a number of industrial applications.Type: GrantFiled: October 21, 2003Date of Patent: February 14, 2006Assignee: The Regents of the University of CaliforniaInventor: Valerie Vreeland
-
Patent number: 6998122Abstract: Novel protein C derivatives are described. These polypeptides retain the biological activity of the wild-type human protein C with substantially longer half-lives in human blood. These polypeptides will require either less frequent administration and/or smaller dosage than wild-type human protein C in the treatment of vascular occlusive disorders, hypercoagulable states, thrombotic disorders and disease states predisposing to thrombosis.Type: GrantFiled: April 13, 2000Date of Patent: February 14, 2006Assignee: Eli Lilly and CompanyInventors: Bruce Edward Gerlitz, Bryan Edward Jones, David Thompson Berg
-
Patent number: 6958387Abstract: This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities.Type: GrantFiled: March 8, 2002Date of Patent: October 25, 2005Assignee: Immunex CorporationInventors: Howard R. G. Clarke, Robert F. DuBose, Steven R. Wiley
-
Patent number: 6953669Abstract: The invention relates to the nucleic acid and polypeptide sequences of two novel human GAK-related gene variants. The invention also relates to the process for producing the polypeptides of the variants. The invention further relates to the use of the nucleic acid and polypeptide sequences of the gene variants in diagnosing diseases associated with the deficiency of GAK gene, in particular, iron homeostasis impairment-related diseases or non-small cell lung cancer (NSCLC), e.g. large cell lung cancer.Type: GrantFiled: March 20, 2002Date of Patent: October 11, 2005Inventor: Ken-Shwo Dai
-
Patent number: 6939710Abstract: This invention relates to an isolated nucleic acid fragment encoding a sulfate assimilation protein. The invention also relates to the construction of a chimeric gene encoding all or a portion of the sulfate assimilation protein in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the sulfate assimilation protein in a transformed host cell.Type: GrantFiled: January 14, 2004Date of Patent: September 6, 2005Assignee: E. I. du Pont de Nemours and CompanyInventors: Saverio Carl Falco, Stephen M. Allen
-
Patent number: 6936245Abstract: Polypeptides capable of regulating signal transduction, which preferably exhibit kinase activity, or antibodies against such polypeptides that inhibit the interaction of these polypeptides with other mediators of signal transduction, may be used in the identification, prevention or treatment of disease, preferably cardiac disease, in mammalian hosts. In addition, these polypeptides can facilitate the identification or isolation of additional mediators of signal transduction associated with disease, preferably cardiac disease, which in turn may also be used in the identification, prevention or treatment of disease, preferably cardiac disease, in mammals.Type: GrantFiled: April 13, 2000Date of Patent: August 30, 2005Assignee: Scios, Inc.Inventors: Wenlin Zeng, Lawrence Stanton, Haiyan Kong